Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine

Journal of Neuroscience

Volumn 26, Issue 2, 2006, Pages 398-405

  Narita, Minoru ^a   Nagumo, Yasuyuki ^a   Hashimoto, Seiko ^a   Narita, Michiko ^a   Khotib, Junaidi ^a   Miyatake, Mayumi ^a   Sakurai, Takeshi ^b   Yanagisawa, Masashi ^c   Nakamachi, Tomoya ^d   Shioda, Seiji ^d   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

Addiction; Dependence; Morphine; Opioid; Orexin; Reward

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (2 METHYLBENZOXAZOL 6 YL) 3 [1.5]NAPHTHYRIDIN 4 YLUREA; DOPAMINE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OREXIN; OREXIN A; OREXIN B; PROTEIN INHIBITOR; RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIALYSATE; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FEMALE; GENE DELETION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RODENT; STATISTICAL SIGNIFICANCE; VENTRAL TEGMENTUM; WILD TYPE;

ANIMALS; BENZOXAZOLES; CONDITIONING, OPERANT; DESIPRAMINE; DOPAMINE; FEMALE; HALOPERIDOL; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIMBIC SYSTEM; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; MICRODIALYSIS; MICROINJECTIONS; MORPHINE; MOTOR ACTIVITY; NEUROPEPTIDES; NUCLEUS ACCUMBENS; OXIDOPAMINE; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; REWARD; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE; UREA; VENTRAL TEGMENTAL AREA;

EID: 32344453801     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2761-05.2006     Document Type: Article

References (40)

1. 2 receptors in nociceptive transmission. Brain Res 543:335-340.
2. Aoki T, Narita M, Ohnishi O, Mizuo K, Narita M, Yajima Y, Suzuki T (2003) Disruption of the type 1 inositol 1,4,5-trisphosphate receptor gene suppresses the morphine-induced antinociception in the mouse. Neurosci Lett 350:69-72.
3. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS (1993) Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264:489-495.
4. Berridge KC (1996) Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 20:1-25.
5. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 28:309-369.
6. Briski KP, Sylvester PW (2001) Co-distribution of Fos- and μ opioid receptor immunoreactivity within the rat septopreoptic area and hypothalamus during acute glucose deprivation: effects of the μ receptor antagonist CTOP. Neurosci Lett 306:141-144.
7. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437-451.
8. Clegg DJ, Air EL, Woods SC, Seeley RJ (2002) Eating elicited by orexin-A, but not melanin-concentrating hormone, is opioid mediated. Endocrinology 143:2995-3000.
9. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Sakurai T, Yanagisawa M, Nakazato M (1999) Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 96:748-753.
10. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett II FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322-327.
11. Delfs JM, Kong H, Mestek A, Chen Y, Yu L, Reisine T, Chesselet MF (1994) Expression of μ opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J Comp Neurol 345:46-68.
12. Fadel J, Deutch AY (2002) Anatomical substrates of orexin-dopamine interaction: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 111:379 -387.
13. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, DiLeone RJ (2003) Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23:3106-3111.
14. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96:10911-10916.
15. Haley MJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12:12-15.
16. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA (2001) Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 103:777-797.
17. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184.
18. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE (2003) Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci 23:7-11.
19. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1987) Autoradiographic differentiation of μ, δ, and κ opioid receptors in the rat forebrain and midbrain. J Neurosci 7:2445-2464.
20. Mansour A, Fox CA, Thompson RC, Akil H, Watson SJ (1994) μ-Opioid receptor mRNA expression in the rat CNS: comparison to μ-receptor binding. Brain Res 643:245-265.
21. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6-25.
22. Matthews RT, German DC (1984) Electrophysiological evidence for the excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 3:617-625.
23. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T (2000) Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 873:181-187.
24. Narita M, Suzuki T, Funada M, Misawa M, Nagase H (1993) Involvement of δ-opioid receptors in the effects of morphine on locomotor activity and the mesolimbic dopaminergic system in mice. Psychopharmacology 111:423-426.
25. Narita M, Funada M, Suzuki T (2001a) Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 89:1-15.
26. Narita M, Mizoguchi H, Suzuki T, Narita M, Dun NJ, Imai S, Yajima Y, Nagase H, Suzuki T, Tseng LF (2001b) Enhanced μ-opioid responses in the spinal cord of mice lacking protein kinase Cγ isoform. J Biol Chem 276:15409-15414.
27. q/11α protein and protein kinase C during the development of sensitization to morphine-induced hyperlocomotion. Neuroscience 111:127-132.
28. Narita M, Ohnishi O, Narita M, Aoki T, Suzuki M, Yajima Y, Funahashi H, Shioda S, Suzuki T (2003) Direct evidence for the activation of phospholipase Cγ1 by in vivo treatment with morphine in the mouse periaqueductal gray matter. Brain Res 970:140-148.
29. Paxinos G, Franklin KBJ (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
30. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. New York: Academic.
31. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996-10015.
32. Phillips AG, LePiane FG, Fibiger HG (1983) Dopaminergic mediation of reward produced by direct injection of enkephalin into the ventral tegmental area of rat. Life Sci 33:2505-2511.
33. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 92:573-585.
34. Shippenberg TS, Herz A (1988) Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol 151:233-242.
35. Shippenberg TS, Bals-Kubik R, Herz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioid: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 265:53-59.
36. Suzuki T, Masukawa Y, Misawa M (1990) Drug interactions in the reinforcing effects of over-the-counter cough syrups. Psychopharmacology 102:438-442.
37. 2+ signaling in dopamine neurons of the ventral tegmental area. NeuroReport 12:1885-1889.
38. van den Pol AN (1999) Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 19:3171-3182.
39. Wilson C, Nomikos GG, Collu M, Fibiger HC (1995) Dopaminergic correlates of motivated behavior: importance of drive. J Neurosci 15:5169-5178.
40. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191-225.